Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal and age-related interstitial lung disease whose etiology and pathogenesis are still largely unknown. It is important to identify IPF patients at high risk of mortality so that early appropriate treatment can improve their prognosis. Therefore, the investigation of available and reliable prognostic biomarkers for IPF is crucial.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- From symptom to diagnosis
Oncology – Thymoma
- Shared decision making
Participatory decision-making using the example of diets for type 1 diabetes
- Patient-centered rounds in medicine
Aligning care with the patient
- Migraine and vascular regulation
CGRP-targeted migraine therapies for vascular risk patients
- Pediatric multiple sclerosis
Early high efficacy as the key to improving prognosis
- Case report, molecular basis and therapeutic implications
HER2-positive colorectal carcinoma with invasive micropapillary component
- Wound Care
Chronically infected wound on the lower leg – a case report
- From symptom to diagnosis